vegfr2/flk2

Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.

Donafenib is a deuterium-labeled Sorafenib (T0093L) which is a multikinase inhibitor (IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).

Sorafenib-13C,D3 (Standard) is a reference standard of Sorafenib-13C,D3 intended for quantitative analysis, quality control, and related biochemical research applications. Sorafenib-13C,d3 is a carbon-13 and deuterium-labeled version of Sorafenib. Sorafenib (Bay 43-9006) is a potent, orally active Raf inhibitor, showing IC50 values of 6 nM for Raf-1 and 20 nM for B-Raf. Additionally, Sorafenib acts as a multi-kinase inhibitor targeting VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit.

Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).

Sorafenib-13C,D3 is a carbon-13 and deuterium-labeled version of Sorafenib. Sorafenib (T0093L) (Bay 43-9006) is a potent, orally active Raf inhibitor, showing IC50 values of 6 nM for Raf-1 and 20 nM for B-Raf. Additionally, Sorafenib (T0093L) acts as a multi-kinase inhibitor targeting VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit.

Sorafenib-D4 is the deuterium labeled Sorafenib. Sorafenib (T0093L) is an inhibitor of multikinase (Raf-1, B-Raf, and VEGFR-3 IC50s of 6 nM, 20 nM, and 22 nM, respectively).